Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 51.55 |
| Open | 51.53 |
| 1-Year Change | -30.92% |
| Day's Range | 51.12 - 51.77 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 51.66 | 0.23 | 0.45% | 51.43 | 51.77 | 50.95 |
| Apr 23, 2024 | 51.55 | -0.29 | -0.56% | 51.84 | 52.07 | 51.25 |
| Apr 22, 2024 | 51.84 | -0.39 | -0.75% | 52.23 | 52.54 | 51.52 |
| Apr 19, 2024 | 52.25 | -0.21 | -0.40% | 52.46 | 52.88 | 51.61 |
| Apr 18, 2024 | 52.74 | 0.10 | 0.19% | 52.64 | 53.06 | 52.20 |
| Apr 17, 2024 | 52.64 | -0.50 | -0.94% | 53.14 | 53.68 | 52.63 |
| Apr 16, 2024 | 53.17 | 0.26 | 0.49% | 52.91 | 54.02 | 52.88 |
| Apr 15, 2024 | 53.36 | -0.55 | -1.02% | 53.91 | 54.24 | 53.34 |
| Apr 12, 2024 | 53.80 | -0.74 | -1.36% | 54.54 | 54.90 | 53.71 |
| Apr 11, 2024 | 54.87 | -0.20 | -0.36% | 55.07 | 55.78 | 54.61 |
| Apr 10, 2024 | 54.94 | 0.31 | 0.57% | 54.63 | 55.18 | 54.41 |
| Apr 9, 2024 | 55.25 | 0.30 | 0.55% | 54.95 | 56.39 | 54.95 |
| Apr 8, 2024 | 54.98 | 0.31 | 0.57% | 54.67 | 55.37 | 54.02 |
| Apr 5, 2024 | 55.18 | 0.71 | 1.30% | 54.47 | 55.35 | 54.04 |
| Apr 4, 2024 | 54.91 | -0.51 | -0.92% | 55.42 | 55.63 | 54.76 |
| Apr 3, 2024 | 55.25 | -0.37 | -0.67% | 55.62 | 56.01 | 54.92 |
| Apr 2, 2024 | 55.78 | -0.44 | -0.78% | 56.22 | 57.10 | 55.71 |
| Apr 1, 2024 | 56.54 | -0.27 | -0.48% | 56.81 | 56.90 | 55.94 |
| Mar 28, 2024 | 56.86 | -0.30 | -0.52% | 57.16 | 57.19 | 56.46 |
| Mar 27, 2024 | 57.03 | 0.50 | 0.88% | 56.53 | 57.16 | 56.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com